Summary
The disposition of tocainide was studied in 15 patients with renal dysfunction. In 9 with total renal failure, the plasma half-life ranged from 16.6 to 42.7 h and total plasma clearance from 35 to 94 ml/min. The longest half-lives were found in 1 patient with cirrhosis, 3 taking the enzyme inhibitor allopurinol, and 1 on cimetidine. The mean half-life in the remaining patients was 22.3±4.8 h (±SD). During a 4 h haemodialysis, the half-life in the 9 patients decreased to 8.5±4.6 h, which was calculated to correspond to removal of 25±14% of the drug from the body. In 6 patients with impaired renal function (creatinine clearance 10–55 ml/min) the tocainide half-life ranged from 13.2 to 22.0 h and total plasma clearance from 72 to 122 ml/min. One patient was taking allopurinol and 1 dihydralazine, and the mean half-life in the others was 19.2±4.0 h. The apparent volume of distribution was similar to that found previously in healthy subjects. The results suggest that tocainide elimination is predictably reduced in patients with renal disease.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York
Graffner C, Conradson T-B, Hofvendahl S, Rydén L (1980) Pharmacokinetics of tocainide following intravenous and oral administration in healthy subjects and in patients with acute myocardial infarction. Clin Pharmacol Ther 27: 64–71
Gwilt PR, Perrier D (1978) Plasma protein binding and distribution characteristics of drugs as indices of their hemodialyzability. Clin Pharmacol Ther 24: 154–161
Laderström P-O, Persson BA (1978) Liquid chromatography in the monitoring of plasma levels of antiarrhythmic drugs. J Chromatogr 149: 331–340
Lalka D, Meyer MB, Duce BR, Elvin AT (1976) Kinetics of the oral antiarrhythmic lidocaine congener, tocainide. Clin Pharmacol Ther 19: 757–766
McDevitt DG, Nies AS, Wilkinson GR, Smith RF, Woosley RL, Oates JA (1976) Antiarrhythmic effects of the lidocaine congener, tocainide, 2-amino-2′, 6′-propionoxylidide, in man. Clin Pharmacol Ther 19: 396–402
Thomson PD, Melmon KL, Richardson JA, Cohn K, Steinbrunn W, Cudihee MD, Rowland M (1973) Lidocaine pharmacokinetics in advanced heart failure, liver disease and renal failure in humans. Ann Intern Med 78: 499–508
Winkle RA, Meffin PJ, Fitzgerald JW, Harrison DC (1976) Clinical efficacy and pharmacokinetics of a new orally effective antiarrhythmic tocainide. Circulation 54: 884–889
Woosley RL, McDevitt DG, Nies AS, Smith RF, Wilkinson GR, Oates JA (1977) Suppression of ventricular ectopic depolarisations by tocainide. Circulation 56: 980–984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wiegers, U., Hanrath, P., Kuck, K.H. et al. Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis. Eur J Clin Pharmacol 24, 503–507 (1983). https://doi.org/10.1007/BF00609893
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609893